Hormonal
Transoral outlet reduction (TORe) delays the postprandial decrease in ghrelin levels by approximately 30 minutes, shifting the nadir from 30 minutes to 60-90 minutes, without significantly altering the total ghrelin exposure (AUC) or correlating with clinical success.
TORe changes *when* you feel hungry after eating, not necessarily *how much* hunger hormone is produced overall. Specifically, it delays the drop in hunger hormones (ghrelin) by about 30 minutes. This might help you feel full a bit longer after a meal, but this specific hormonal change does not predict whether you will successfully lose weight.
In all analyses, the typical postprandial decrease in ghrelin levels was delayed by 30 minutes... The absence of significant changes in the AUCs of ghrelin levels also corroborates that... ghrelin response is unrelated to CS and no specific baseline behavior or cut-off threshold can be used as a predictor of better response to TORe.
Why this rating
Consistent finding across groups but small sample size and lack of predictive value for weight loss outcomes.
Source
Endoscopic transoral outlet reduction induces enterohormonal changes in patients with weight regain after Roux-en-Y gastric bypass
Vitor Brunaldi et al. · Endoscopy International Open · 2024
DOI 10.1055/a-2312-5742
More from this paper
- Transoral outlet reduction (TORe) using argon plasma coagulation (APC) induces a significant increase in postprandial peptide YY (PYY) levels, particularly in patients who have undergone cholecystectomy, whereas APC combined with suturing does not produce this effect.Moderate
- One year after TORe, patients experience a significant overall decrease in postprandial Glucagon-like peptide-1 (GLP-1) levels, regardless of the specific technique used (APC vs. suture) or clinical success status.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →